… in particular with newer antithrombotic medicines. We have … studied if dual or triple combination
of antithrombotic agents exert similar effects on coagulation activation in an in vivo model …

… sequence, subject (sequence), period and, treatment effects … , studies investigating the direct
factor Xa inhibitor apixaban (… DEEM) in addition to antiplatelet therapy in patients with ACS …

… from participants were spiked ex vivo with apixaban 0 (APIX0), … the antiplatelet effects of
current antiplatelet treatments … of potential participants from consecutive patients admitted to the …

… sponse ex vivo, using the Badimon perfusion chamber system … Thrombus and antiplatelet
therapy in type 2 diabetes mellitus… Xa inhibitor apixaban for symptomatic deep vein thrombosis. …

… oral anticoagulant and antiplatelet therapy. Any combination … Thrombus targeting was
confirmed using IVIS in vivo imaging … TAP was designed according to published sequence …

… for thrombus formation and targets for oral antithrombotic … effects in in vitro assays and
enhances antithrombotic efficacy … • Apixaban added to standard antiplatelet therapy increased the …

… Antithrombotic therapy plays a key role in the treatment of … a prospective, open-label,
parallel-group PD study enrolling 80 … Apixaban 2.5 mg twice daily and 10 mg once daily resulted …

… and has two tyrosines in a conserved sequence known as an … vivo, alone and in combination
with apixaban, a factor Xa … , and ex vivo platelet-rich thrombus formation under conditions …

… groups showed no benefit from antithrombotic treatment with … A multi-national, open-label,
single-arm, phase 3 trial was underta… of altering this sequence on its interaction with FSAP. …

… to 1 of 6 doubleblind apixaban dosage schedules [5, 10 or … , double-blind DU-176b and
open-label warfarin safety study … , Apixaban, in combination with antiplatelet therapy after acute …